227 related articles for article (PubMed ID: 25560732)
1. Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): from bench to bedside.
Abdel-Rahman O
Crit Rev Oncol Hematol; 2015 Apr; 94(1):45-54. PubMed ID: 25560732
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy: a new hope for thyroid carcinomas.
Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
[TBL] [Abstract][Full Text] [Related]
3. Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.
Narayanan S; Colevas AD
Curr Treat Options Oncol; 2016 Jun; 17(6):30. PubMed ID: 27139457
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Yeung KT; Cohen EE
Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
[TBL] [Abstract][Full Text] [Related]
5. An update on molecular biology of thyroid cancers.
Omur O; Baran Y
Crit Rev Oncol Hematol; 2014 Jun; 90(3):233-52. PubMed ID: 24405857
[TBL] [Abstract][Full Text] [Related]
6. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Smolle E; Taucher V; Petru E; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
[TBL] [Abstract][Full Text] [Related]
7. An update on clinical trials of targeted therapies in thyroid cancer.
Haraldsdottir S; Shah MH
Curr Opin Oncol; 2014 Jan; 26(1):36-44. PubMed ID: 24240178
[TBL] [Abstract][Full Text] [Related]
8. New therapeutic advances in the management of progressive thyroid cancer.
Woyach JA; Shah MH
Endocr Relat Cancer; 2009 Sep; 16(3):715-31. PubMed ID: 19218279
[TBL] [Abstract][Full Text] [Related]
9. A new appraisal of iodine refractory thyroid cancer.
Vaisman F; Carvalho DP; Vaisman M
Endocr Relat Cancer; 2015 Dec; 22(6):R301-10. PubMed ID: 26307020
[TBL] [Abstract][Full Text] [Related]
10. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene.
Belletti B; Ferraro P; Arra C; Baldassarre G; Bruni P; Staibano S; De Rosa G; Salvatore G; Fusco A; Persico MG; Viglietto G
Oncogene; 1999 Aug; 18(34):4860-9. PubMed ID: 10490819
[TBL] [Abstract][Full Text] [Related]
11. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.
Kojic KL; Kojic SL; Wiseman SM
Expert Rev Anticancer Ther; 2012 Mar; 12(3):345-57. PubMed ID: 22369326
[TBL] [Abstract][Full Text] [Related]
12. [Refractory thyroid cancers].
Schlumberger M; Chougnet C; Baudin E; Leboulleux S;
Presse Med; 2011 Dec; 40(12 Pt 1):1189-98. PubMed ID: 22078085
[TBL] [Abstract][Full Text] [Related]
13. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies in advanced differentiated thyroid cancer.
Carneiro RM; Carneiro BA; Agulnik M; Kopp PA; Giles FJ
Cancer Treat Rev; 2015 Sep; 41(8):690-8. PubMed ID: 26105190
[TBL] [Abstract][Full Text] [Related]
15. Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications.
Keefe SM; Cohen MA; Brose MS
Clin Cancer Res; 2010 Feb; 16(3):778-83. PubMed ID: 20103668
[TBL] [Abstract][Full Text] [Related]
16. [Targeted therapy in thyroid cancer: Towards a treatment card].
Lkhoyaali S; Benhmida S; Ait Elhaj M; Layachi M; Bensouda Y; Errihani H
Pathol Biol (Paris); 2015 Feb; 63(1):1-6. PubMed ID: 25555494
[TBL] [Abstract][Full Text] [Related]
17. Update on thyroid cancer treatment.
Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
[TBL] [Abstract][Full Text] [Related]
18. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review.
Anderson RT; Linnehan JE; Tongbram V; Keating K; Wirth LJ
Thyroid; 2013 Apr; 23(4):392-407. PubMed ID: 23294230
[TBL] [Abstract][Full Text] [Related]
19. Novel targeted therapies and immunotherapy for advanced thyroid cancers.
Naoum GE; Morkos M; Kim B; Arafat W
Mol Cancer; 2018 Feb; 17(1):51. PubMed ID: 29455653
[TBL] [Abstract][Full Text] [Related]
20. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma.
Brose MS; Smit J; Capdevila J; Elisei R; Nutting C; Pitoia F; Robinson B; Schlumberger M; Shong YK; Takami H
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1137-47. PubMed ID: 23098114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
